vs

Side-by-side financial comparison of Amalgamated Financial Corp. (AMAL) and Immunocore Holdings plc (IMCR). Click either name above to swap in a different company.

Immunocore Holdings plc is the larger business by last-quarter revenue ($104.5M vs $85.2M, roughly 1.2× Amalgamated Financial Corp.). On growth, Immunocore Holdings plc posted the faster year-over-year revenue change (24.3% vs 9.4%). Amalgamated Financial Corp. produced more free cash flow last quarter ($134.4M vs $-35.5M). Over the past eight quarters, Immunocore Holdings plc's revenue compounded faster (21.7% CAGR vs 4.3%).

CI Financial is a Canadian investment management company based in Toronto, Ontario. It offers investment management and wealth management services targeted to high net worth retail investors, as well as brokerage and trading services to portfolio managers and institutional investors.

Immunocore is a global commercial-stage biotechnology company, based in Oxfordshire, which researches and develops biological drugs using soluble T-cell receptor technology.

AMAL vs IMCR — Head-to-Head

Bigger by revenue
IMCR
IMCR
1.2× larger
IMCR
$104.5M
$85.2M
AMAL
Growing faster (revenue YoY)
IMCR
IMCR
+14.9% gap
IMCR
24.3%
9.4%
AMAL
More free cash flow
AMAL
AMAL
$169.9M more FCF
AMAL
$134.4M
$-35.5M
IMCR
Faster 2-yr revenue CAGR
IMCR
IMCR
Annualised
IMCR
21.7%
4.3%
AMAL

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
AMAL
AMAL
IMCR
IMCR
Revenue
$85.2M
$104.5M
Net Profit
Gross Margin
97.4%
Operating Margin
39.0%
-18.8%
Net Margin
Revenue YoY
9.4%
24.3%
Net Profit YoY
EPS (diluted)
$0.88
$-0.61

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AMAL
AMAL
IMCR
IMCR
Q4 25
$85.2M
$104.5M
Q3 25
$85.6M
$103.7M
Q2 25
$80.9M
$98.0M
Q1 25
$77.0M
$93.9M
Q4 24
$77.9M
$84.1M
Q3 24
$81.0M
$80.2M
Q2 24
$78.5M
$75.4M
Q1 24
$78.3M
$70.5M
Net Profit
AMAL
AMAL
IMCR
IMCR
Q4 25
Q3 25
$26.8M
$-177.0K
Q2 25
$26.0M
$-10.3M
Q1 25
$25.0M
$5.0M
Q4 24
Q3 24
$27.9M
$8.7M
Q2 24
$26.8M
$-11.6M
Q1 24
$27.2M
$-24.4M
Gross Margin
AMAL
AMAL
IMCR
IMCR
Q4 25
97.4%
Q3 25
99.5%
Q2 25
98.9%
Q1 25
99.1%
Q4 24
99.6%
Q3 24
99.4%
Q2 24
97.7%
Q1 24
99.7%
Operating Margin
AMAL
AMAL
IMCR
IMCR
Q4 25
39.0%
-18.8%
Q3 25
42.9%
-6.9%
Q2 25
43.8%
-15.2%
Q1 25
45.1%
-3.9%
Q4 24
42.4%
-23.1%
Q3 24
47.2%
-10.6%
Q2 24
45.6%
-21.2%
Q1 24
49.2%
-37.6%
Net Margin
AMAL
AMAL
IMCR
IMCR
Q4 25
Q3 25
31.3%
-0.2%
Q2 25
32.1%
-10.5%
Q1 25
32.5%
5.4%
Q4 24
Q3 24
34.5%
10.9%
Q2 24
34.1%
-15.4%
Q1 24
34.8%
-34.7%
EPS (diluted)
AMAL
AMAL
IMCR
IMCR
Q4 25
$0.88
$-0.61
Q3 25
$0.88
$0.00
Q2 25
$0.84
$-0.20
Q1 25
$0.81
$0.10
Q4 24
$0.78
$-0.47
Q3 24
$0.90
$0.17
Q2 24
$0.87
$-0.23
Q1 24
$0.89
$-0.49

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AMAL
AMAL
IMCR
IMCR
Cash + ST InvestmentsLiquidity on hand
$291.2M
$864.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$794.5M
$381.0M
Total Assets
$8.9B
$1.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AMAL
AMAL
IMCR
IMCR
Q4 25
$291.2M
$864.2M
Q3 25
$115.5M
$892.4M
Q2 25
$171.1M
$882.8M
Q1 25
$65.7M
$837.0M
Q4 24
$60.7M
$820.4M
Q3 24
$149.2M
$901.3M
Q2 24
$58.0M
$859.6M
Q1 24
$155.2M
$832.8M
Total Debt
AMAL
AMAL
IMCR
IMCR
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$438.7M
Q2 24
$452.5M
Q1 24
$452.5M
Stockholders' Equity
AMAL
AMAL
IMCR
IMCR
Q4 25
$794.5M
$381.0M
Q3 25
$775.6M
$396.6M
Q2 25
$754.0M
$388.5M
Q1 25
$736.0M
$378.5M
Q4 24
$707.7M
$360.7M
Q3 24
$698.2M
$377.8M
Q2 24
$646.0M
$359.1M
Q1 24
$616.8M
$359.5M
Total Assets
AMAL
AMAL
IMCR
IMCR
Q4 25
$8.9B
$1.1B
Q3 25
$8.7B
$1.1B
Q2 25
$8.6B
$1.1B
Q1 25
$8.3B
$1.0B
Q4 24
$8.3B
$1.0B
Q3 24
$8.4B
$1.1B
Q2 24
$8.3B
$1.0B
Q1 24
$8.1B
$994.0M
Debt / Equity
AMAL
AMAL
IMCR
IMCR
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
1.16×
Q2 24
1.26×
Q1 24
1.26×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AMAL
AMAL
IMCR
IMCR
Operating Cash FlowLast quarter
$135.8M
$-32.7M
Free Cash FlowOCF − Capex
$134.4M
$-35.5M
FCF MarginFCF / Revenue
157.8%
-34.0%
Capex IntensityCapex / Revenue
1.6%
2.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$229.4M
$-15.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AMAL
AMAL
IMCR
IMCR
Q4 25
$135.8M
$-32.7M
Q3 25
$39.5M
$-4.5M
Q2 25
$24.9M
$26.0M
Q1 25
$34.2M
$435.0K
Q4 24
$124.1M
$-14.0M
Q3 24
$35.8M
$21.1M
Q2 24
$28.0M
$23.5M
Q1 24
$31.3M
$-4.6M
Free Cash Flow
AMAL
AMAL
IMCR
IMCR
Q4 25
$134.4M
$-35.5M
Q3 25
$38.3M
$-5.2M
Q2 25
$24.2M
$25.6M
Q1 25
$32.5M
$137.0K
Q4 24
$122.3M
$-17.5M
Q3 24
$35.2M
$20.3M
Q2 24
$27.8M
$23.1M
Q1 24
$31.1M
$-5.0M
FCF Margin
AMAL
AMAL
IMCR
IMCR
Q4 25
157.8%
-34.0%
Q3 25
44.7%
-5.0%
Q2 25
29.9%
26.1%
Q1 25
42.2%
0.1%
Q4 24
157.0%
-20.9%
Q3 24
43.4%
25.3%
Q2 24
35.4%
30.7%
Q1 24
39.7%
-7.1%
Capex Intensity
AMAL
AMAL
IMCR
IMCR
Q4 25
1.6%
2.8%
Q3 25
1.4%
0.7%
Q2 25
0.9%
0.4%
Q1 25
2.3%
0.3%
Q4 24
2.3%
4.3%
Q3 24
0.7%
1.0%
Q2 24
0.3%
0.4%
Q1 24
0.3%
0.6%
Cash Conversion
AMAL
AMAL
IMCR
IMCR
Q4 25
Q3 25
1.47×
Q2 25
0.96×
Q1 25
1.37×
0.09×
Q4 24
Q3 24
1.28×
2.42×
Q2 24
1.05×
Q1 24
1.15×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons